Dalin Martin G, Desrichard Alexis, Katabi Nora, Makarov Vladimir, Walsh Logan A, Lee Ken-Wing, Wang Qingguo, Armenia Joshua, West Lyndsay, Dogan Snjezana, Wang Lu, Ramaswami Deepa, Ho Alan L, Ganly Ian, Solit David B, Berger Michael F, Schultz Nikolaus D, Reis-Filho Jorge S, Chan Timothy A, Morris Luc G T
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Clin Cancer Res. 2016 Sep 15;22(18):4623-33. doi: 10.1158/1078-0432.CCR-16-0637. Epub 2016 Apr 21.
Salivary duct carcinoma (SDC) is an aggressive salivary malignancy, which is resistant to chemotherapy and has high mortality rates. We investigated the molecular landscape of SDC, focusing on genetic alterations and gene expression profiles.
We performed whole-exome sequencing, RNA sequencing, and immunohistochemical analyses in 16 SDC tumors and examined selected alterations via targeted sequencing of 410 genes in a second cohort of 15 SDCs.
SDCs harbored a higher mutational burden than many other salivary carcinomas (1.7 mutations/Mb). The most frequent genetic alterations were mutations in TP53 (55%), HRAS (23%), PIK3CA (23%), and amplification of ERBB2 (35%). Most (74%) tumors had alterations in either MAPK (BRAF/HRAS/NF1) genes or ERBB2 Potentially targetable alterations based on supportive clinical evidence were present in 61% of tumors. Androgen receptor (AR) was overexpressed in 75%; several potential resistance mechanisms to androgen deprivation therapy (ADT) were identified, including the AR-V7 splice variant (present in 50%, often at low ratios compared with full-length AR) and FOXA1 mutations (10%). Consensus clustering and pathway analyses in transcriptome data revealed striking similarities between SDC and molecular apocrine breast cancer.
This study illuminates the landscape of genetic alterations and gene expression programs in SDC, identifying numerous molecular targets and potential determinants of response to AR antagonism. This has relevance for emerging clinical studies of ADT and other targeted therapies in SDC. The similarities between SDC and apocrine breast cancer indicate that clinical data in breast cancer may generate useful hypotheses for SDC. Clin Cancer Res; 22(18); 4623-33. ©2016 AACR.
涎腺导管癌(SDC)是一种侵袭性涎腺恶性肿瘤,对化疗耐药且死亡率高。我们研究了SDC的分子图谱,重点关注基因改变和基因表达谱。
我们对16例SDC肿瘤进行了全外显子测序、RNA测序和免疫组化分析,并通过对另一组15例SDC进行410个基因的靶向测序来检测选定的改变。
SDC的突变负荷高于许多其他涎腺癌(1.7个突变/Mb)。最常见的基因改变是TP53突变(55%)、HRAS突变(23%)、PIK3CA突变(23%)以及ERBB2扩增(35%)。大多数(74%)肿瘤在MAPK(BRAF/HRAS/NF1)基因或ERBB2中存在改变。基于支持性临床证据的潜在可靶向改变存在于61%的肿瘤中。雄激素受体(AR)在75%的肿瘤中过表达;确定了几种对雄激素剥夺治疗(ADT)的潜在耐药机制,包括AR-V7剪接变体(存在于50%的肿瘤中,与全长AR相比通常比例较低)和FOXA1突变(10%)。转录组数据的共识聚类和通路分析显示SDC与分子大汗腺癌之间存在显著相似性。
本研究阐明了SDC中的基因改变和基因表达程序,确定了众多分子靶点以及对AR拮抗反应的潜在决定因素。这与SDC中ADT和其他靶向治疗的新兴临床研究相关。SDC与大汗腺癌之间的相似性表明,乳腺癌的临床数据可能为SDC产生有用的假设。《临床癌症研究》;22(18);4623 - 33。©2016美国癌症研究协会。